Breaking News Instant updates and real-time market news.

ALDR

Alder Biopharmaceuticals

$11.50

0.07 (0.61%)

08:11
07/11/19
07/11
08:11
07/11/19
08:11

Alder presents new data from PROMISE-1, PROMISE-2 Phase 3 trial analyses

Alder BioPharmaceuticals announced new data from post-hoc analyses of its PROMISE-1 and PROMISE-2 Phase 3 clinical trials for eptinezumab, an investigational monoclonal antibody developed for the prevention of migraine. Detailed data will be shared at the American Headache Society's 61st Annual Scientific Meeting in Philadelphia that further support eptinezumab's clinical profile, including data on migraine-free months, migraine severity and quality of life. The 100% responder rate analyses evaluated the efficacy of eptinezumab in terms of the number of months a patient experienced no migraine days, i.e., the number of migraine-free months, during the one-year study period in the PROMISE-1 trial and the six-month study period in the PROMISE-2 trial. At baseline, patients enrolled in PROMISE-1 were experiencing 8.6 mean monthly migraine days per month and patients in PROMISE-2 were experiencing 16.1 mean monthly migraine days per month. Post-hoc analyses were conducted that quantified the number of patients who experienced no migraine days during each month in the trial study period. Highlights include: PROMISE-1: 18.1% of episodic migraine patients treated with 100 mg of eptinezumab and 25.2% of those treated with 300 mg of eptinezumab experienced no migraine days for at least half of the study period compared with 12.6% of placebo-treated patients; 63.3% of episodic migraine patients treated with 100 mg of eptinezumab and 64.4% of those treated with 300 mg achieved at least one migraine-free month compared to 47.7% of those on placebo. PROMISE-2; 14.0% of chronic migraine patients treated with 100 mg of eptinezumab and 19.1% of those treated with 300 mg of eptinezumab experienced no migraine days for at least half of the study period compared with 4.9% of placebo-treated patients. 34.6 % of chronic migraine patients treated with 100 mg of eptinezumab and 39.7% of those treated with 300 mg achieved at least one migraine-free month compared to 22.4% of those on placebo; About twice as many patients with chronic migraine were 100% responders with eptinezumab than with placebo during any given month of the trial.

  • 09

    Sep

  • 21

    Feb

ALDR Alder Biopharmaceuticals
$11.50

0.07 (0.61%)

04/04/19
PIPR
04/04/19
NO CHANGE
PIPR
Overweight
Piper Jaffray stays Overweight on Alder Biopharma, Amgen after Novartis filing
Piper Jaffray analyst Christopher Raymond maintains his Overweight rating on Alder Biopharma (ALDR) and Amgen (AMGN) after the filing by Novartis (NVS) alleging legal dispute with the latter about their migraine collaboration. The analyst says that Novartis tried to beat Amgen to the punch after entering agreement with Alder to manufacture eptinezumab, which prompted Amgen to terminate their commercialization agreement. Raymond adds that a resolution of this dispute could take a year or more but believes that investors may conclude that the spat reflects the value of anti-CGRP assets.
04/18/19
PIPR
04/18/19
NO CHANGE
PIPR
Teva gains ground on Amgen in latest migraine survey, says Piper Jaffray
Following of survey of 99 neurologists done by his firm's partner Spherix Global Insights, Piper Jaffray analyst Christopher Raymond maintains an Overweight rating on Amgen (AMGN) and a Neutral rating on Teva Pharmaceutical (TEVA). The migraine survey indicates Eli Lilly's (LLY) Emgality is lagging and that Teva's Ajovy appears to be gaining ground on Amgen's Aimovig across numerous metrics, Raymond tells investors in a research note. While one data point does not a trend make, this move warrants close attention, especially given the increased significance assigned to Aimovig with respect to Amgen sentiment, says the analyst. Raymond, however, remains cautious on Teva shares given the" lack of clarity regarding when/where EBITDA will hit a trough." On the R&D side, the analyst notes that Overweight-rated Alder Biopharmaceuticals' (ALDR) eptinezumab "appears to be particularly top-of-mind among migraine specialists."
05/28/19
LEER
05/28/19
INITIATION
Target $21
LEER
Outperform
Alder Biopharmaceuticals initiated with an Outperform at SVB Leerink
SVB Leerink analyst Marc Goodman initiated Alder Biopharmaceuticals with an Outperform and $21 price target.
07/10/19
FBCO
07/10/19
INITIATION
Target $14
FBCO
Neutral
Alder Biopharmaceuticals assumed with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman assumed coverage of Alder Biopharmaceuticals with a Neutral rating and $14 price target.

TODAY'S FREE FLY STORIES

LPL

LG Display

$7.45

0.275 (3.83%)

18:51
07/22/19
07/22
18:51
07/22/19
18:51
Periodicals
Breaking Periodicals news story on LG Display »

LG Display to invest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

F

Ford

$10.02

-0.03 (-0.30%)

18:51
07/22/19
07/22
18:51
07/22/19
18:51
Periodicals
Ford to spend $50M to upgrade Chicago plant for SUVs, Reuters reports »

Ford intends to invest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 23

    Oct

BRO

Brown & Brown

$34.64

-0.11 (-0.32%)

, SNAP

Snap

$14.14

0.12 (0.86%)

18:48
07/22/19
07/22
18:48
07/22/19
18:48
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Brown…

BRO

Brown & Brown

$34.64

-0.11 (-0.32%)

SNAP

Snap

$14.14

0.12 (0.86%)

INTC

Intel

$51.36

1.1 (2.19%)

QCOM

Qualcomm

$75.93

0.9 (1.20%)

STLD

Steel Dynamics

$31.55

0.09 (0.29%)

ZION

Zions Bancorp

$45.16

-0.95 (-2.06%)

CDNS

Cadence Design

$72.68

-0.21 (-0.29%)

SNPS

Synopsys

$135.42

0.41 (0.30%)

WHR

Whirlpool

$148.30

0.085 (0.06%)

AMTD

TD Ameritrade

$52.41

0.82 (1.59%)

ACAD

Acadia

$25.97

0.28 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 22

    Jul

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 25

    Jul

  • 31

    Jul

  • 31

    Jul

  • 03

    Aug

  • 06

    Aug

  • 20

    Aug

  • 21

    Aug

  • 26

    Sep

  • 27

    Sep

SNAP

Snap

$14.14

0.12 (0.86%)

18:35
07/22/19
07/22
18:35
07/22/19
18:35
Upgrade
Snap rating change  »

Snap upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 03

    Aug

SMBC

Southern Missouri Bancorp

$31.95

-0.3 (-0.93%)

18:33
07/22/19
07/22
18:33
07/22/19
18:33
Earnings
Southern Missouri Bancorp sees Q4 EPS 81c, consensus 77c »

Southern Missouri…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

SSRM

SSR Mining

$15.80

-0.06 (-0.38%)

18:32
07/22/19
07/22
18:32
07/22/19
18:32
Hot Stocks
SSR Mining to acquire remaining 25% interest in Puna Operations »

SSR Mining announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

SNAP

Snap

$14.14

0.12 (0.86%)

18:23
07/22/19
07/22
18:23
07/22/19
18:23
Upgrade
Snap rating change at Stifel »

Snap upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 03

    Aug

HD

Home Depot

$211.23

-1.79 (-0.84%)

18:22
07/22/19
07/22
18:22
07/22/19
18:22
Hot Stocks
Home Depot CFO: The company is in great hands »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

AN

AutoNation

$42.01

-0.045 (-0.11%)

18:21
07/22/19
07/22
18:21
07/22/19
18:21
Hot Stocks
Breaking Hot Stocks news story on AutoNation »

AutoNation down 2.6%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 13

    Nov

AN

AutoNation

$42.01

-0.045 (-0.11%)

18:17
07/22/19
07/22
18:17
07/22/19
18:17
Earnings
AutoNation reports Q2 cont ops EPS $1.12, consensus $1.06 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 13

    Nov

CR

Crane

$86.50

0.99 (1.16%)

18:15
07/22/19
07/22
18:15
07/22/19
18:15
Earnings
Crane backs FY19 adjusted EPS view of $6.25-$6.45, consensus $6.41 »

Backs FY19 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 09

    Sep

  • 09

    Sep

CR

Crane

$86.50

0.99 (1.16%)

18:14
07/22/19
07/22
18:14
07/22/19
18:14
Earnings
Crane Co. reports Q2 EPS ex-items $1.58, consensus $1.56 »

Reports Q2 revenue $842M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 09

    Sep

  • 09

    Sep

AN

AutoNation

$42.01

-0.045 (-0.11%)

, GOOG

Alphabet

$1,138.09

8.09 (0.72%)

18:11
07/22/19
07/22
18:11
07/22/19
18:11
Hot Stocks
AutoNation names Cheryl Miller CEO »

AutoNation (AN) announced…

AN

AutoNation

$42.01

-0.045 (-0.11%)

GOOG

Alphabet

$1,138.09

8.09 (0.72%)

GOOGL

Alphabet Class A

$1,139.52

7.85 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Jul

  • 25

    Jul

  • 03

    Aug

  • 08

    Aug

  • 27

    Oct

  • 13

    Nov

STLD

Steel Dynamics

$31.55

0.09 (0.29%)

18:04
07/22/19
07/22
18:04
07/22/19
18:04
Hot Stocks
Steel Dynamics reports Q2 operating income $295M, down 6% from Q1 »

Q2 average external…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 06

    Aug

FBMS

First Bancshares

$29.74

-0.105 (-0.35%)

18:03
07/22/19
07/22
18:03
07/22/19
18:03
Hot Stocks
First Bancshares announces agreement to acquires First Florida Bancorp »

The First Bancshares,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

STLD

Steel Dynamics

$31.55

0.09 (0.29%)

18:03
07/22/19
07/22
18:03
07/22/19
18:03
Hot Stocks
Steel Dynamics CEO sees 'modest growth' for steel consumption in second half »

CEO Mark Millett says:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 06

    Aug

STLD

Steel Dynamics

$31.55

0.09 (0.29%)

18:01
07/22/19
07/22
18:01
07/22/19
18:01
Earnings
Steel Dynamics reports Q2 EPS 87c, consensus 89c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 06

    Aug

FDEF

First Defiance Financial

$27.22

-0.04 (-0.15%)

17:58
07/22/19
07/22
17:58
07/22/19
17:58
Earnings
First Defiance Financial reports Q2 EPS 61c, consensus 58c »

"Solid loan growth,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

QCOM

Qualcomm

$75.93

0.9 (1.20%)

, INTC

Intel

$51.36

1.1 (2.19%)

17:58
07/22/19
07/22
17:58
07/22/19
17:58
Hot Stocks
Qualcomm falls after news Apple may buy Intel smartphone-modem chip business »

Shares of Qualcomm (QCOM)…

QCOM

Qualcomm

$75.93

0.9 (1.20%)

INTC

Intel

$51.36

1.1 (2.19%)

AAPL

Apple

$207.21

4.59 (2.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 03

    Aug

SPY

SPDR S&P 500 ETF Trust

$297.82

0.65 (0.22%)

, SPX

S&P 500

$0.00

(0.00%)

17:51
07/22/19
07/22
17:51
07/22/19
17:51
General News
Trump tweets budget deal reached with no poison pills »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$297.82

0.65 (0.22%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAFD

Washington Federal

$34.85

-0.12 (-0.34%)

17:46
07/22/19
07/22
17:46
07/22/19
17:46
Hot Stocks
Washington Federal raises dividend 5% »

Washington Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBMS

First Bancshares

$29.74

-0.105 (-0.35%)

17:46
07/22/19
07/22
17:46
07/22/19
17:46
Earnings
First Bancshares reports Q2 EPS ex-items 79c, consensus 69c »

M. Ray "Hoppy"…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

NTDOY

Nintendo

$0.00

(0.00%)

17:43
07/22/19
07/22
17:43
07/22/19
17:43
Periodicals
Law firm sues Nintendo over Joy-Con drift, Polygon reports »

Chimicles Schwartz Kriner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OEC

Orion Engineered

$18.41

0.05 (0.27%)

17:33
07/22/19
07/22
17:33
07/22/19
17:33
Hot Stocks
Orion Engineered announces price increases »

Orion Engineered Carbons…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 06

    Aug

HMST

HomeStreet

$27.76

-0.03 (-0.11%)

17:31
07/22/19
07/22
17:31
07/22/19
17:31
Earnings
HomeStreet reports Q2 core EPS 13c, consensus 52c »

"The second quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.